Wedbush Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS)
Equities researchers at Wedbush assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $8.00 price target on the biotechnology company’s stock. Wedbush’s price target points to a potential upside of 447.95% from the company’s current […]
Equities researchers at Wedbush assumed coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) in a report released on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $8.00 price target on the biotechnology company’s stock. Wedbush’s price target points to a potential upside of 447.95% from the company’s current […]
